Article Text

Download PDFPDF
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding
  1. Ethan Mar1,
  2. Kerry Taylor2 and
  3. Peter Mollee1
  1. 1Department of Haematology, Metro South Hospital and Health Service, Woolloongabba, Queensland, Australia
  2. 2Icon Cancer Care, Mater Medical Centre, Brisbane, Queensland, Australia
  1. Correspondence to Dr Ethan Mar; ethanmar06{at}gmail.com

Abstract

We report a case of progressive light-chain amyloidosis (otherwise known as AL amyloidosis) with acquired factor X (aFX) deficiency with a complete haematological response and rapid normalisation of FX levels following daratumumab monotherapy. To our knowledge, this is the first case report documenting successful treatment with daratumumab of aFX deficiency secondary to AL amyloidosis. The patient responded well to this therapy, with excellent symptomatic and quality of life improvements as well as a reduction in bleeding manifestations. This case highlights the value in considering daratumumab treatment when AL amyloidosis is complicated by FX deficiency.

  • haematology (incl blood transfusion)
  • genetics

Statistics from Altmetric.com

Footnotes

  • Contributors EODM wrote the manuscript, collated references and provided the final editing of the case report. KT reviewed the manuscript and provided clinical details. PM also reviewed the manuscript and edited relevant clinical details.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.